BMYBristol-Myers SquibbFinished
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 2,747 (final count)
- Started
- Aug 5, 2015
- Main results expected
- Oct 25, 2024
- Fully finished
- Oct 25, 2024
- Results posted
- Oct 30, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival Per BICR
Measured over: From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)
Overall Survival
Measured over: From randomization untill death or last follow up whichever occurs first (up to approximately 481 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02477826 · record last updated 2025-10-30 · checked 2026-11-09 15:42 UTC